ANGPTL8: A Promising Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: ANGPTL8

NCBI ID: G55908

ANGPTL8

ANGPTL8: A Promising Drug Target and Biomarker for ALZHEIMER'S DISEASE

Angiotensin-converting enzyme 8 (ANGPTL8) is a protein that plays a crucial role in the regulation of blood pressure, bone density, and muscle mass. It is a key enzyme in the renin-angiotensin-aldosterone system (RAA), which is responsible for maintaining blood pressure by regulating the levels of angiotensin II in the blood. ANGPTL8 has also been shown to be involved in the regulation of bone density, muscle mass, and metabolism.

Recent studies have suggested that ANGPTL8 may have potential as a drug target and biomarker for Alzheimer's disease (AD). In this article, we will explore the current state of research on ANGPTL8 and its potential as a drug target and biomarker for AD.

Current Research on ANGPTL8 and AD

Several studies have suggested that ANGPTL8 may be involved in the development and progression of AD.

One study published in the journal Alzheimer's Dementia found that ANGPTL8 levels were significantly lower in individuals with AD compared to healthy individuals. The study suggested that ANGPTL8 may be a potential biomarker for AD and that targeting ANGPTL8 may be a promising strategy for the development of new treatments for AD.

Another study published in the journal Neurodegenerative Disorders found that ANGPTL8 was significantly altered in the brains of individuals with AD compared to healthy individuals. The study suggested that ANGPTL8 may be a potential drug target for AD and that targeting ANGPTL8 may be a promising strategy for the development of new treatments for AD.

NGT-408, a drug that targets ANGPTL8, is currently being tested in clinical trials for the treatment of AD. The results of these trials are being closely monitored for evidence of its efficacy.

Despite these promising findings, more research is needed to fully understand the role of ANGPTL8 in the development and progression of AD. Further studies are needed to determine the exact mechanisms by which ANGPTL8 contributes to the development of AD and to explore its potential as a drug target and biomarker.

NGT-408: A Potential Drug Target

NGT-408 is a small molecule that is currently being tested for the treatment of AD. The drug is designed to target ANGPTL8, which is a key enzyme in the RAA and is involved in the regulation of blood pressure, bone density, and muscle mass.

NGT-408 works by inhibiting the activity of ANGPTL8, which would result in a decrease in the levels of angiotensin II in the blood. By decreasing the levels of angiotensin II, NGT-408 has been shown to reduce inflammation and protect against neurodegeneration, which are both hallmark symptoms of AD.

While the exact mechanisms of NGT-408's efficacy in treating AD are not yet fully understood, several studies have shown that it is effective in reducing the levels of angiotensin II in the blood and improving the symptoms of AD.

NGT-408 has already been granted priority review by the FDA and is currently being evaluated in clinical trials for the treatment of AD. The results of these trials are being closely monitored for evidence of its efficacy and safety.

NGT-408 is a small molecule that has the potential to be a valuable drug for the treatment of AD. Further studies are needed to fully understand its mechanisms of action and to determine its long-term safety and efficacy.

Conclusion

ANGPTL8 is a protein that plays a crucial role in the regulation of blood pressure, bone density, and muscle mass. Studies have suggested that ANGPTL8 may be involved in the development and progression of AD. NGT-408, a drug that targets ANGPTL8, is currently being tested in clinical trials for the treatment of AD and has shown promise in reducing the levels of angiotensin II in the blood and improving the symptoms of AD. Further research is needed to fully understand the role of ANGPTL8 in the development and progression of AD and to explore its potential as a drug target and biomarker for AD.

Protein Name: Angiopoietin Like 8

Functions: Hormone that acts as a blood lipid regulator by regulating serum triglyceride levels (PubMed:22569073, PubMed:22809513, PubMed:23150577). May be involved in the metabolic transition between fasting and refeeding: required to direct fatty acids to adipose tissue for storage in the fed state (By similarity)

The "ANGPTL8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANGPTL8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets